Glimeripide insulin secretagogues

Description Results NMA

glimepiride (4 mg once daily). (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 26 weeks

CV death 1.00 [0.38; 2.62]

All-cause mortality 1.00 [0.38; 2.62]

Stroke 1.00 [0.38; 2.62]

Myocardial infarction 1.00 [0.38; 2.62]

glimepiride, 1, 4, or 8 mg once daily (n=304)

vs.

placebo (n=0)

double-blind

Parallel groups

Sample size: 304/0

Primary endpoint:

FU duration: 14 weeks

glimepiride at individually determined optimal dose (1-8 mg of glimepiride) for 10+12 weeks (n=123)

vs.

placebo (n=126)

double-blind

Parallel groups

Sample size: 123/126

Primary endpoint:

FU duration:

glimepiride 8 mg q.d., 4 mg b.i.d., 16 mg q.d., or 8 mg b.i.d (n=416)

vs.

placebo (n=0)

double-blind

Parallel groups

Sample size: 416/0

Primary endpoint:

FU duration: 14 weeks

glimepiride with titration to 2 mg and 4 mg for FPG levels >120 mg/dL (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: change in HbA(1c)

FU duration: 14 weeks

metformin and glimepiride (n=-9)

vs.

metformin (n=-9)

metformin, glimepiride or metformin and glimepiride

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration:

glimepiride 0.25mg od, 0.5mg od (n=62)

vs.

placebo (n=31)

Sample size: 62/31

Primary endpoint:

FU duration:

glimepiride 1-8mg od (n=122)

vs.

placebo (n=125)

Sample size: 122/125

Primary endpoint:

FU duration:

Glimepiride (16 mg/day) plus insulin (n=72)

vs.

insulin plus placebo (n=73)

Sample size: 72/73

Primary endpoint:

FU duration:

glimepiride 1-4mg od (n=96)

vs.

gliclazide 80-320 mg/day (od or bid) (n=107)

Sample size: 96/107

Primary endpoint:

FU duration:

glimepiride 1 mg daily (n=524)

vs.

2.5 mg glibenclamide (n=520)

double-blind

Parallel groups

Sample size: 524/520

Primary endpoint: not unique

FU duration:

glimepiride 1-16mg od (n=289)

vs.

non-micronized glyburide 1.25-20mg od (n=288)

double-blind

Parallel groups

Sample size: 289/288

Primary endpoint:

FU duration:

glimepiride (n=172)

vs.

gliclazide or glibenclamide (n=0)

open

Parallel groups

Sample size: 172/0

Primary endpoint:

FU duration: 6 months

glimepiride 1-8mg od (n=427)

vs.

glibenclamide 1.75-14 mg/day (od or bid) (n=425)

Sample size: 427/425

Primary endpoint:

FU duration:

glimepiride 1-16 mg/day (od or bid) (n=444)

vs.

glipizide 2.5-40 mg/day (od or bid) (n=208)

Sample size: 444/208

Primary endpoint:

FU duration:

glimepirid e6mg od (n=50)

vs.

glimepiride 3mg bid (n=48)

Cross over

Sample size: 50/48

Primary endpoint:

FU duration: